USA Update on Paclitaxel in Ovarian Cancer

References

• Alberts D S, Green S, Hannigan E V, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706–17
   PubMed Web of Science ®Google Scholar
• Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718–26
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, McGuire W P, Donehower R C. The current status of Taxol. Principles and Practice of Gynecologic Oncology Updates, W J Hoskins, C A Perez, R C Young, 1993; Vol. 1: 1–16
   Google Scholar
• McGuire W P, Rowinsky E K, Rosenshein N B, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111: 273–9
   PubMed Web of Science ®Google Scholar
• Thigpen T, Blessing J, Ball H, et al. Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a gynecologic oncology group study, Abstract. Proc ASCO 1990; 9: 604
   Google Scholar
• Trimble E L, Adams J D, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405–10
   PubMed Web of Science ®Google Scholar
• Kohn E C, Sarosy G, Bicher A, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18–24
   PubMed Web of Science ®Google Scholar
• Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al. Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group, Abstract 810. Proc ASCO 1993; 12: 256
   Google Scholar
• Rowinsky E K, Gilbert M R, McGuire W P, et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–703
   PubMed Web of Science ®Google Scholar
• McGuire W P, Hoskins W J, Brady M F, et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC). The Gynecologic Oncology Group (GOG), Abstract 808. Proc ASCO 1993; 12: 255
   Google Scholar
• Tropé C, Bertelsen K, Simonsen E, et al. A phase II, multi-center, non-randomized study of paclitaxel (Taxol) in patients with previously untreated FIGO stage III sub-optimally resected ovarian cancer. Abstract SP 19. Proc NFOG Congress. 1994
   Google Scholar
• Salmi T, Bertelsen K, Bjorkholm E, et al. Phase II, multi-center, non-randomized study of paclitaxel (Taxol) in patients with ovarian cancer previously treated with platinum, Abstract SP20. Proc NFOG Congress. 1994
   Google Scholar
• Ozols R F, Kilpatrick D, O'Dwyer P, et al. Phase I and pharmacokinetic study of Taxol (T) and carboplatin (C) in previously untreated patients (PTS) with advanced epithelial ovarian cancer (OC): a pilot study of the Gynecologic Oncology Group, Abstract 824. Proc ASCO 1993; 12: 259
   Google Scholar
• Calvert A H, Newell D R, Gumbrell L A, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56
   PubMed Web of Science ®Google Scholar
• Ozols R F, Thigpen J T, Dauplat J, et al. Dose intensity. Ann Oncol 1993; 4: S49–56
   PubMedGoogle Scholar
• Schilder R J. High-dose chemotherapy with autologous hematopoietic cell support in gynecologic malignancies. Principles and Practice of Gynecologic Oncology Updates, W J Hoskins, C A Perez, R C Young, 1993; Vol. 1: 1–14
   Google Scholar
• Schiller J H, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241–8
   PubMed Web of Science ®Google Scholar
• van der Burg M EL, van Lent M, Kobierska A, et al. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC): an EORTC Gynecological Cancer Cooperative Group (GCCG) study, Abstract 818. Proc ASCO 1993; 12: 258
   Google Scholar
• Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485–91
   PubMed Web of Science ®Google Scholar
• Schilder R J, et al. Protocol 91032. Fox Chase Cancer Center, Philadelphia 1994
   Google Scholar